Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

How HBA’s Woman Of The Year Became A Successful Leader
How HBA’s Woman Of The Year Became A Successful Leader As Jennifer Cook strides across the stage at the Hilton New York Midtown, it is difficult to envision the 2016 Healthcare Businesswomen’s Association’s (HBA) Woman of the Year (WOTY) as being anything but extremely confident. But during her acceptance speech, the Roche executive paints a very different portrait of her early self. “When I was growing up, I was shy, very studious, and quite frankly, insecure,” she admits.  Continue Reading...
Are You Ready For HBA WOTY 2016?
Are You Ready For HBA WOTY 2016? On Thursday, May 12, the Healthcare Businesswomen’s Association (HBA) will host its 27th annual Woman of the Year (WOTY) at the Hilton New York Midtown. The celebration draws over 2,000 women and men from throughout the healthcare industry and showcases the HBA’s core purpose of furthering the advancement and impact of women in the business of healthcare. For those who have never attended, the ceremony involves much more than the...  Continue Reading...
Your BIO Convention 2016 Planning Guide
Your BIO Convention 2016 Planning Guide Having begun my preparations for the upcoming BIO 2016 International Convention, June 6 – 9 at the Moscone Center in San Francisco, I thought I would share some insights to help with your planning. First, in case you weren’t aware, the Moscone Center consists of three separate buildings: Moscone Center West, North, and South (see map here). While this might not seem like a big deal, if you plan on attending some of the educational...  Continue Reading...
Tackling Rising Healthcare Costs Requires Less Talk And More Action
Tackling Rising Healthcare Costs Requires Less Talk And More Action Last October when we asked industry thought leaders, “What would be hot for 2016” (see our December 2015 issue), drug pricing was one topic consistently mentioned. Probably not much of a surprise considering the mass media’s fascination with portraying former Turing CEO Martin Shkreli as being everything that’s bad with biopharma. But the reality is that controversy over drug pricing has been around for as long as there...  Continue Reading...
Are You Ready To Go Beyond The Cutting Edge At BIO 2016?
Are You Ready To Go Beyond The Cutting Edge At BIO 2016? Being the 2015 educational planning committee co-chair for BIO provided behind the scenes insights into what makes for a good industry session proposal at BIO. But beyond that I also learned how important it is for those interested in putting together an educational session for a conference to begin the planning process early. So when Bayer’s VP and Head of the company’s east coast innovation center, Chandra Ramanathan, Ph.D., and I...  Continue Reading...
What Does The Successful Killing Of The Pfizer Allergan Deal Mean?
What Does The Successful Killing Of The Pfizer Allergan Deal Mean? When I wrote the opinion piece on the U.S. government’s successful killing of the planned Pfizer Allergan merger, it was on the heels of a March Editor’s Note on the current state of U.S. corporate taxes. There are those who argue that U.S. companies aren’t seeking to invert due to high U.S. tax rates. And while we can dispute the rationale behind why companies have been seeking to relocate outside the United States, what...  Continue Reading...
Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game
Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game At a recent conference* I overheard an executive comment that the clinical trial space remains one of the biggest bottlenecks to successful drug development. Sure, companies are developing much more sophisticated and targeted therapies. However, one of the problems this more individualized drug development creates is a slowdown in clinical trial recruitment. While new technologies are creating an enormous amount of clinical evidence, for the...  Continue Reading...
Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional?
Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional? In the March 2016 issue of Life Science Leader magazine, my Editor’s Note, The U.S. Tax Man Cometh, The U.S. Corporations Leaveth, referenced the Pfizer-Allergan merger as pretty much a done deal. Little did I know then that the U.S. government would stoop to implementing government policies more familiar to those living in the former U.S.S.R., than a country founded on freedom and famous for supporting free enterprise. While not losing...  Continue Reading...
Are You Committed To Being A Better Leader?
Are You Committed To Being A Better Leader? I recently cracked open Leadership Vertigo, a book by S. Max Brown and Tanveer Naseer. I was immediately enthralled when the authors hit me with this tidbit. “Gallup research has found that the top 25 percent of teams (i.e., the best managed) versus the bottom 25 percent in any workplace (i.e., the worst managed), have nearly 50 percent fewer accidents and 41 percent fewer quality defects.”  Continue Reading...
The Best Pharma Manufacturing Conference You’ve Never Heard Of
The Best Pharma Manufacturing Conference You’ve Never Heard Of Thanks to Outsourced Pharma chief editor Louis Garguilo taking the lead on serving as host of Life Science Leader magazine’s annual CMO Leadership Awards celebration and reception in New York City, my time was suddenly freed up to explore for new educational opportunities. And while I will admit to being biased as to the quality of educational opportunities offered by our own Outsourced Pharma conferences, I recently got back from an event ...  Continue Reading...